PRZ-ROSUVASTATIN TABLET
国: カナダ
言語: 英語
ソース: Health Canada
製品の特徴
(SPC)
23-09-2020
この製品の一部のドキュメントは現在利用できません。カスタマーサービスにリクエストを送信できます。入手可能になり次第、お知らせします。
リクエストを送信します。
リクエストを送信します。
有効成分:
ROSUVASTATIN (ROSUVASTATIN CALCIUM)
から入手可能:
PHARMARIS CANADA INC
ATCコード:
C10AA07
INN（国際名）:
ROSUVASTATIN
投薬量:
40MG
医薬品形態:
TABLET
構図:
ROSUVASTATIN (ROSUVASTATIN CALCIUM) 40MG
投与経路:
ORAL
パッケージ内のユニット:
15G/50G
処方タイプ:
Prescription
治療領域:
HMG-COA REDUCTASE INHIBITORS
製品概要:
Active ingredient group (AIG) number: 0148963003; AHFS:
認証ステータス:
APPROVED
承認日:
2020-09-25
製品の特徴
Page 1 of 43
PRODUCT MONOGRAPH
PR
PRZ-ROSUVASTATIN
Rosuvastatin Calcium Tablets, USP
Tablets: 5 mg, 10 mg, 20 mg and 40 mg of rosuvastatin (as rosuvastatin
calcium)
Lipid Metabolism Regulator
Pharmaris Canada Inc.
8310-130 Street, Suite 102,
Surrey, British Columbia
Canada V3W 8J9
DATE OF PREPARATION: September 23,
2020
CONTROL NO: 234091
Page 2 of 43
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
........................................................ 3
SUMMARY PRODUCT INFORMATION
................................................................. 3
INDICATIONS AND CLINICAL
USE.......................................................................
3
CONTRAINDICATIONS
............................................................................................
4
WARNINGS AND PRECAUTIONS
..........................................................................
5
ADVERSE REACTIONS
..........................................................................................
10
DRUG INTERACTIONS
...........................................................................................
14
DOSAGE AND ADMINISTRATION
.......................................................................
21
OVERDOSAGE
.........................................................................................................
23
ACTION AND CLINICAL PHARMACOLOGY
..................................................... 23
STORAGE AND STABILITY
..................................................................................
25
DOSAGE FORMS, COMPOSITION AND PACKAGING
...................................... 26
PART II: SCIENTIFIC INFORMATION
.............................................................................
27
PHARMACEUTICAL INFORMATION
.................................................................. 27
CLINICAL
TRIALS...................................................................................................
28
DETAILED PHARMACOLOGY
..............................................................................
31
TOXICO
完全なドキュメントを読む
